
Report 9618 - Appendix 2 - Anaphylaxis: Recommendations for prioritization at-risk groups for SARS-CoV-2 Vaccination (Phase 1b)
In this scientific advisory report, which offers guidance to public health policy-makers, the Belgian Superior Health Council highlights the priorities for vaccinating at-risk patients against COVID-19 (Phase Ib). This report aims at providing the Belgian Immunization Strategy and Operationalization Taskforce and general practitioners with specific recommendations on strategic COVID-19 vaccination in Belgium.
With contributions from Pr. Vito Sabato, Tim De Cloet, Pr. Didier Ebo, Pr. Pierre Van Damme, Pr. Antoine Froidure (on behalf of BelSACI), Pr. Jean-Michel Dogné – Version approved by the NITAG Vaccination during the meeting of 21/01/2021.
-
Report 9618 - Vaccination Covid19 Anaphylaxis
English20210201_shc-9618_annexe2_anaphylaxis_vapprouveenitag-belsaci.pdf PDF document - 195.79 KB
-
Advies 9618 - Vaccinatie Covid19 Anafylaxie
Dutch20210201_hgr-9618_annexe2_anaphylaxis_vapprouveenitag-belsaci.pdf PDF document - 188.1 KB
-
Avis 9618 - Vaccination Covid19 Anaphylaxie
French20210201_css-9618_annexe2_anaphylaxis_vapprouveenitag-belsaci.pdf PDF document - 185.71 KB
-
Stellungnahme 9618 - Impfung Covid19 Anaphylaxie
German20210201_hgr-9618_annexe2_anaphylaxis_vapprouveenitag-belsaci_de.pdf PDF document - 197.62 KB